The Promise of Discovery Season 4, Episode 4

This research examines mGlu7, a transmembrane receptor involved in several neurodevelopmental disorders, such as Rett syndrome, ADHD, schizophrenia, and Neurofibromatosis Type 1. The project discussed studies the mechanism of mGlu7 activation by allosteric modulators to develop new treatments and help guide drug discovery efforts.

Featuring: Xia Lei, Ph.D., postdoctoral fellow, Vanderbilt University

Interviewer: Colleen Niswender, Ph.D., associate professor of Pharmacology; Director of Molecular Pharmacology, Warren Center for Neuroscience Drug Discovery; and a Vanderbilt Kennedy Center Member

Activation Mechanisms for Context-Dependent Allosteric Modulation of the mGlu7 receptor

The Vanderbilt Kennedy Center (VKC) facilitates discoveries and best practices to improve the lives of individuals with intellectual and developmental disabilities and their families. More than 200 faculty affiliated with Vanderbilt University and Vanderbilt University Medical Center are engaged in multidisciplinary research, training, technical assistance, and dissemination. The VKC’s Treatment and Research Institute for Autism Spectrum Disorders (TRIAD) works to improve assessment and treatment services for children with autism while advancing knowledge and training.